Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faecium
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
We studied an ampicillin- and vancomycin-resistant Enterococcus faecium (VRE) isolate from a patient with endocarditis and bacteremia refractory to treatment with daptomycin (6 mg/kg of body weight) plus linezolid. Blood cultures cleared within 24 h of changing therapy to daptomycin (12 mg/kg) plus ampicillin. We examined the effects of ampicillin on daptomycin-induced growth inhibition and killing, surface charge, and susceptibility to several prototypical host defense cationic antimicrobial peptides. MICs and time-kill curves with daptomycin were assessed in the presence and absence of ampicillin. The impact of ampicillin on surface charge was assessed by flow cytometry and a poly- l -lysine binding assay. The effects of ampicillin preexposures upon VRE killing by five distinct cationic peptides of different structure, charge, origin, and mechanism of action were analyzed using the epidermal cathelicidin LL-37, thrombin-induced platelet microbicidal proteins (tPMPs), and a synthetic congener modeled after tPMP microbicidal domains (RP-1), human neutrophil peptide-1 (hNP-1), and polymyxin B (bacteria derived). Fluoroscein-Bodipy-labeled daptomycin was used to evaluate daptomycin binding to VRE membranes in the presence or absence of ampicillin. In media containing ampicillin (25 to 100 mg/liter), daptomycin MICs decreased from 1.0 to 0.38 mg/liter. Based on time-kill analysis and an in vitro pharmacodynamic model, ampicillin enhanced daptomycin activity against the study VRE from a bacteriostatic to a bactericidal profile. VRE grown in ampicillin (25 to 150 mg/liter) demonstrated an incremental reduction in its relative net positive surface charge. When grown in the presence (versus absence) of ampicillin (25 and 100 mg/liter), the VRE strain (i) was more susceptible to killing by LL-37, tPMPs, hNP-1, and RP-1 but not to polymyxin B and (ii) exhibited greater binding to Bodipy-labeled daptomycin. We conclude that ampicillin induces reductions in net positive bacterial surface charge of VRE, correlating with enhanced bactericidal effects of cationic calcium-daptomycin and a diverse range of other cationic peptides in vitro . While the mechanism(s) of such β-lactam-mediated shifts in surface charge remains to be defined, these finding suggest a potential for β-lactam-mediated enhancement of activity of both daptomycin and innate host defense peptides against antibiotic-resistant bacteria.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of in vitro evaluations [214][215][216] suggested that ampicillin and ceftaroline in combination with daptomycin demonstrate the greatest synergistic activity compared with other β-lactam-daptomycin combinations.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Mechanisms of Antimicrobial Peptide Action and Resistance
Yeaman, M. R., & Yount, N. Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.2 · Cited by 3,001 · cited 1×
“Such an effect is supported by our earlier demonstration of additive in vitro interactions between -lactam or glycopeptide antibiotics with cationic host defense peptides against a number of Enterococcus strains (47, 49).”
BackgroundSelf-citationVancomycin Resistance in Gram-Positive Cocci
Courvalin, P. (2006) · Clinical Infectious Diseases · doi:10.1086/491711 · Cited by 1,028 · cited 1×
“Although hypothetical at this point, it is also feasible that the substitution of D-alanine by D-lactate in VRE within the peptidoglycan pentapeptide precursor concomitantly results in an increased anionic surface charge of the organism (10) and thereby contributes to greater surface binding of cationic peptides, such…”
BackgroundGenetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454 · cited 2×
“Given the potential of the surface charge to impact the interaction of cationic calcium-daptomycin (17) with the enterococcal membrane, the capacity of ampicillin to alter this parameter was examined.”
BackgroundGenetic Basis for In Vivo Daptomycin Resistance in Enterococci
Arias, C. A., Panesso, D., McGrath, D. M., Qin, X., Mojica, M. F., Miller, C., Diaz, L., Tran, T. T., Rincon, S., Barbu, E. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011138 · Cited by 377 · cited 1×
“aureus with different genotypic changes (2, 3, 32, 36).”
BackgroundDvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358 · cited 2×
“These antibiotic concentrations were chosen to encompass readily achievable free serum concentrations of each agent during clinical treatment regimens (11, 14, 18).”
Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., & Bayer, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00719-07 · Cited by 318 · cited 2×
“aureus has commonly been associated with coevolution of reduced susceptibility to killing by a variety of host defense molecules, such as cationic antimicrobial peptides (22, 34).”
BackgroundSelf-citationDaptomycin‐Resistant, Methicillin‐Resistant Staphylococcus aureus Bacteremia
Mangili, A., Bica, I., Snydman, D. R., & Hamer, D. H. (2005) · Clinical Infectious Diseases · doi:10.1086/428616 · Cited by 256
Fabretti, F., Theilacker, C., Baldassarri, L., Kaczynski, Z., Kropec, A., Holst, O., & Huebner, J. (2006) · Infection and Immunity · doi:10.1128/iai.00111-06 · Cited by 255 · cited 1×
“A lack of D-alanylated LTA may, in turn, result in an enhancement of the relative net negative envelope charge and, thus, increased susceptibility to killing by daptomycin and other cationic peptides (16).”
BackgroundDhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252 · cited 1×
“aureus (MRSA) strains in vitro, as well as in animal models of endocarditis (44) and in several cases of refractory MRSA bacteremia (12).”
BackgroundSelf-citationPogliano, J., Osborne, N., Sharp, M. D., Abanes‐De Mello, A., Perez, A., Sun, Y., & Pogliano, K. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01255.x · Cited by 246 · cited 2×
“Issaquah, WA) as previously described (36).”
BackgroundSelf-citationDevelopment of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus
Hayden, M. K., Rezai, K., Hayes, R. A., Lolans, K., Quinn, J. P., & Weinstein, R. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5285-5287.2005 · Cited by 241
Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy
Sabol, K., Patterson, J. E., Lewis, J. S., Owens, A., Cadena, J., & Jorgensen, J. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1664-1665.2005 · Cited by 209 · cited 2×
“There have been a number of recent reports of isolation of daptomycin-resistant Staphylococcus aureus (17, 20–23, 27–29, 31, 39, 41) and enterococcus strains (24, 26) emerging during daptomycin treatment in patients with recalcitrant infections.”
BackgroundMarty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., & Pillai, S. K. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.595-597.2006 · Cited by 199
Genetic Basis for Daptomycin Resistance in Enterococci
Palmer, K. L., Daniel, A., Hardy, C., Silverman, J., & Gilmore, M. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00207-11 · Cited by 189 · cited 1×
“aureus has commonly been associated with coevolution of reduced susceptibility to killing by a variety of host defense molecules, such as cationic antimicrobial peptides (22, 34).”
BackgroundTreatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin
Skiest, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.655-656.2006 · Cited by 167
Blaser, J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.125 · Cited by 156
Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Kelesidis, T., Humphries, R., Uslan, D. Z., & Pegues, D. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq113 · Cited by 146 · cited 2×
“There have been a number of recent reports of isolation of daptomycin-resistant Staphylococcus aureus (17, 20–23, 27–29, 31, 39, 41) and enterococcus strains (24, 26) emerging during daptomycin treatment in patients with recalcitrant infections.”
BackgroundPharmacokinetics of Sulbactam/Ampicillin in Humans: A Review
Foulds, G. (1986) · Clinical Infectious Diseases · doi:10.1093/clinids/8.supplement_5.503 · Cited by 137 · cited 2×
“These antibiotic concentrations were chosen to encompass readily achievable free serum concentrations of each agent during clinical treatment regimens (11, 14, 18).”
Moise, P. A., North, D. S., Steenbergen, J. N., & Sakoulas, G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70200-2 · Cited by 130
Self-citationYang, S.-J., Xiong, Y. Q., Boyle-Vavra, S., Daum, R., Jones, T., & Bayer, A. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-10 · Cited by 130
Self-citationJulian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00559-07 · Cited by 119
Xiong, Y. Q., Mukhopadhyay, K., Yeaman, M. R., Adler-Moore, J., & Bayer, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3114-3121.2005 · Cited by 118
Self-citationTsuji, B. T., & Rybak, M. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2735-2745.2005 · Cited by 113
Self-citationDaptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci
Rand, K. H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh104 · Cited by 112 · cited 1×
“(3, 8, 13, 30, 37), a combined daptomycin-ampicillin therapeutic regimen was employed for this patient.”
MethodXiong, Y.-Q., Yeaman, M. R., & Bayer, A. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1111 · Cited by 107
Self-citationMukhopadhyay, K., Whitmire, W., Xiong, Y. Q., Molden, J., Jones, T., Peschel, A., Staubitz, P., Adler-Moore, J., McNamara, P. J., Proctor, R. A., et al. (2007) · Microbiology · doi:10.1099/mic.0.2006/003111-0 · Cited by 92 · cited 1×
“metric method as previously described (22, 33).”
Self-citationSynthetic Peptides That Exert Antimicrobial Activities in Whole Blood and Blood-Derived Matrices
Yeaman, M. R., Gank, K. D., Bayer, A. S., & Brass, E. P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3883-3891.2002 · Cited by 90
Self-citationMechanisms of Resistance to Daptomycin in Enterococcus faecium
Montero, C. I., Stock, F., & Murray, P. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00774-07 · Cited by 74 · cited 1×
“aureus with different genotypic changes (2, 3, 32, 36).”
BackgroundYeaman, M. R., Norman, D. C., & Bayer, A. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.8.1665 · Cited by 71 · cited 1×
“aureus strains by combinations of cell wall-active antibiotics (oxacillin) plus cationic tPMPs (42, 46).”
BackgroundSelf-citationVikram, H. R., Havill, N. L., Koeth, L. M., & Boyce, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5384-5387.2005 · Cited by 71
Seidl, K., Bayer, A. S., Fowler, V. G., McKinnell, J. A., Abdel Hady, W., Sakoulas, G., Yeaman, M. R., & Xiong, Y. Q. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-10 · Cited by 69 · cited 1×
“It is also conceivable that ampicillin may affect biofilm formation in vivo, which may also have played a role in the clearance of bacteremia, given the importance of this phenotype in endocarditis and persistent bacteremia (38).”
BackgroundSelf-citationMariani, P. G., Sader, H. S., & Jones, R. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl256 · Cited by 62
Entenza, J. M., Giddey, M., Vouillamoz, J., & Moreillon, P. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.022 · Cited by 61 · cited 1×
“In this regard, recent data have demonstrated that ampicillin can suppress the emergence of daptomycin resistance in enterococci in vitro, also suggesting a favorable interaction between these two antibiotics (15).”
BackgroundHarigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., & Tsuji, B. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01585-08 · Cited by 55 · cited 1×
“brain heart infusion (BHI) broth, delivery of antibiotic, and collection of bacterial and antimicrobial samples (19).”
BackgroundSelf-citationYeaman, M. R., Sullam, P. M., Dazin, P. F., & Bayer, A. S. (1994) · Infection and Immunity · doi:10.1128/iai.62.8.3416-3423.1994 · Cited by 51 · cited 1×
“aureus adherence to platelets, a mechanism used by this organism as a potential immune subversion strategy (48).”
BackgroundSelf-citationHirschwerk, D., Ginocchio, C. C., Bythrow, M., & Condon, S. (2006) · Infection Control & Hospital Epidemiology · doi:10.1086/502688 · Cited by 49 · cited 1×
“Daptomycin, a cyclic lipopeptide antibiotic, associates with calcium to form a cationic complex that targets the bacterial cytoplasmic membrane, causing rapid membrane depolarization and subsequent lethality against susceptible Gram-positive organisms (21).”
BackgroundBactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium
Mobarakai, N. K., Quale, J. M., & Landman, D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.385 · Cited by 44 · cited 1×
“(3, 8, 13, 30, 37), a combined daptomycin-ampicillin therapeutic regimen was employed for this patient.”
MethodCilli, F., Aydemir, S., & Tunger, A. (2006) · Journal of Chemotherapy · doi:10.1179/joc.2006.18.1.27 · Cited by 42
Bingen, É., Lambert-Zechovsky, N., Leclercq, R., Doit, C., & Mariani‐Kurkdjian, P. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/26.5.619 · Cited by 38
Çilli, F., Aydemir, Ş., & Tünger, A. (2006) · Journal of Chemotherapy · doi:10.1179/joc.2008.18.1.27 · Cited by 17
Al-Obeid, S., Gutmann, L., & Williamson, R. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.10.1901 · Cited by 16 · cited 1×
“Those authors speculated that ampicillin may prompt the release of lipoteichoic acid (LTA) from the cell envelope which, in turn, could either increase cell wall autolysin activity or reduce substrate availability for dlt-mediated LTA D-alanylation (1).”
BackgroundDuez, J.-M., Péchinot, A., Siébor, E., Cordin, X., & Kazmierczak, A. (1989) · PubMed · Cited by 6
Research works printed but not linked: 4
- CashmanKA BayerAS YeamanMR. 1998. Diversity in susceptibility to antibiotics and cationic peptides among Enterococcus faecalis or Enterococcus faecium isolates of diverse clinical or geographic origin, abstr. A-26. Abstr. 98th Gen. Meet. Am. Soc. Microbiol., Atlanta, GA. American Society for Microbiology, Washington, DC.
- CashmanKA HooperDC BayerAS KooSP YeamanMR. 1999. In vitro resistance to vancomycin and endogenous cationic antimicrobial peptides are independent phenotypes in clinical isolates of Enterococcus faecium, abstr. A-93. Abstr. 99th Gen. Meet. Am. Soc. Microbiol., Chicago, IL. American Society for Microbiology, Washington, DC.
- CashmanKA BayerAS YeamanMR. 1999. Diversity of platelet microbicidal protein susceptibility in Enterococcus. California State University Press Long Beach CA.
- YeamanMR. 2002. Code among chaos in antimicrobial resistance: lessons from host defense proteins, p 10. Keystone Symposium on Molecular and Cellular Biololgy, Santa Fe, NM. Keystone Symposia, Silverthorne, CO.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationThe Enterococcus: a Model of Adaptability to Its Environment
García-Solache, M., & Rice, L. B. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-18 · Cited by 754
“The mechanism(s) underlying this apparent synergism remains unclear, although in some instances, greater binding of daptomycin to the cell membrane was seen in the presence of ampicillin (286).”
BackgroundMechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
“The inverse relationship between DAP susceptibility and sensitivity to b-lactams [71], combinations of cephalosporins and fosfomycin [135] and the synergy between DAP and rifampicin [123] could provide a way to ‘hold the line’ against the rising tide of resistance.”
BackgroundCrank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
Antimicrobial Peptides: Features, Action, and Their Resistance Mechanisms in Bacteria
Moravej, H., Moravej, Z., Yazdanparast, M., Heiat, M., Mirhosseini, A., Moosazadeh Moghaddam, M., & Mirnejad, R. (2018) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0392 · Cited by 410
“145 Accordingly, ampicillin induces reductions in net positive bacterial surface charge, correlating with enhanced bactericidal effects of daptomycin and other cationic peptides in vitro .”
Metadata
- Authors
- Sakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A.
- Affiliations
- University of California San Diego (US)
- University of California, Los Angeles (US)
- University at Buffalo, State University of New York (US)
- Cubist Pharmaceuticals (United States) (US)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-02
- Volume
- 56
- Issue
- 2
- Pages
- 838-844
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3264218
- OpenAlex
- W1970747983
- Semantic Scholar
- a8694fec622eb4c65c230450ea41146ea8cf35fd
- Cited by
- 176
- References
- 43
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 2 · 2023: 4 · 2022: 13 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 16 · 2017: 16 · 2016: 16 · 2015: 24 · 2014: 16 · 2013: 17 · 2012: 10
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Astellas Pharma
- Pfizer Pharmaceuticals
- National Institute of General Medical Sciences (R01GM073898)
- National Institute of Allergy and Infectious Diseases (R01 AI-39018, R01 AI-48031, R01AI048031)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- ampicillin, daptomycin, Enterococcus faecium, vancomycin resistance, antimicrobial synergy, cationic antimicrobial peptides, antimicrobial peptides, LL-37, polymyxin B, bacterial surface charge, bactericidal activity, endocarditis, bacteremia
- MeSH terms
- Ampicillin, Anti-Bacterial Agents, Drug Synergism, Drug Therapy, Combination, Endocarditis, Bacterial, Humans, Microbial Sensitivity Tests, Models, Biological, Vancomycin, Bacteremia, Treatment Outcome, Enterococcus faecium, Daptomycin, Vancomycin Resistance, Antimicrobial Cationic Peptides, Drug Resistance, Bacterial, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.